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In the course of development of new anticoagulants, an indandione derivative has been subjected to a clinical evaluation. The new agent is one of the most potent hypoprothrombinemic substance known but it is readily counteracted with vitamin K. The agent was administered to a large series of patients with thromboembolic diseases and control of anticoagulant therapy was observed to be simple, reproducible, with a good predictability of response as well as with absence of toxic phenomena and a low order of bleeding complications. It has been administered to 11 patients for ambulant anticoagulant care for periods up to 18 months with satisfactory results and it appears to be especially suitable for long-term maintenance therapy.
IN the treatment of thromboembolic diseases the use of anticoagulants has become an established modality. It is generally agreed that the popularity and application of this class of drugs would be increased if several disadvantages in the existing drugs could be overcome.1-4 The ideal anticoagulant still awaited is one which (a) can be given orally, (b) has rapid anticoagulant effect, attaining therapeutic levels in minutes or hours and (c) almost as rapidly the anticoagulant effect can During the two years of study on the wards of the Los Angeles County General Hospital approximately 75 patients were selected for control single-dose studies. The acutely ill and those with hepatic and renal diseases and blood dyscrasias were omitted. The patients were unselected as to sex and age. The antidotal effect of vitamin K was studied on some of these subjects. A second group of 109 subjects received the drug as specific therapy for some thromboembolic disease.
FIELD, GOLDFARB, WARE AND GRIFFITH
The following studies were conducted on each patient during the use of Dipaxin: frequent urine examinations, blood counts, liver function tests (cephalin flocculation, thymol turbidity, total protein and albumin-globulin ratio) and nonprotein nitrogen levels of plasma.
The drug was given orally in the form of 1 and 10 mg. tablets.
RESULTS

Effect of Single Doses of Dipaxin
The plasma prothrombin levels were measured daily in patients given single doses of Dipaxin. These results are summarized in Initial Therapy. Several different combinations of first and second day dosage were applied in order to achieve the most rapid and efficient prothrombin-reducing schedule. Ultimately it was observed that first-day dosage of from 20 to 30 mg. followed by 10 to 15 mg. the second day would induce an effective and usually therapeutic hypoprothrombinemia within 48 hours. In many cases at the option of the ward staff, heparin was also administered and some patients initially given Dicumarol were transferred to maintenance of hypoprothrombinemia with Dipaxin. Maintenance Therapy. For maintenance therapy, in the average patient, it was found convenient to follow a sliding scale of dosages based on the prothrombin level observed on the day of therapy. This plan was applied successfully on a number of the wards of the hospital by the resident staff otherwise unfamiliar with the effects of Dipaxin. This schedule was helpful in maintaining prothrombin concentrations on most patients over long periods of time. Table 5 outlines the dosage plan.
Results. As the major criterion it is necessary to state the defined requirement of this laboratory for adequate therapeutic hypoprothrombinemia, and this is considered to be a prothrombin level of between 10 and 30 per cent. Upon this definition most of the following data are founded. Table 6 gives the analysis of distribution of patients based on the total dosage of Dipaxin given and duration of maintenance of dosage.
As an index of the distribution of the dosage required by individual patients in order to maintain the desired prothrombin levels, 1. Patient J. B. developed two episodes of bleeding: (a) Small ecchymoses appeared on the lower extremities during the first month. These subsided while on therapy.
(b) Microscopic hematuria associated with prothrombin less than 10 per cent developed in the fifth month of therapy. Drug discontinued and 100 mg. vitamin K1 given and symptoms ceased immediately ( fig. 1). 2. Patient E. T. developed occasional mild gingival bleeding from second to eighth month With this in mind, on an ambulant basis it has been possible with Dipaxin to maintain excellent therapeutic hypoprothrombinemia for a period of three months or longer in a group of 11 patients. In fact, of the initial group, two patients remain on Dipaxin therapy about 18 months after its initiation at the time of this writing.
The disease states included representatives of most conditions given above. The patients were not only ward patients of the Los Angeles County Hospital but two were private patients whose therapy was begun and maintained at home. Although, as customary, with limited availability of prothrombin assays, estimations were done daily while the patients were hospitalized. At discharge, they were maintained on the daily dose of Dipaxin which appeared most suitable. Initially they were seen in the Clinic once weekly, subsequently once every two or even three weeks; when prothrombin assays were done, they were issued the drug.
From time to time, blood and urine examinations were also done as a control measure.
Only occasionally was it necessary to make some change in the established daily dose to keep the prothrombin level in the desired 10 140%r coagulants heretofore used at this center, Dipaxin would appear to be the equal of, or more satisfactory than, others for general usage.
It appears that on a weight basis, Dipaxin is about 15 times more potent in man than Dicumarol, but in general its hypoprothrombinemia resembles closely that induced by Dicumarol. Using the initial dose schedule as outlined, 51 per cent of all patients had achieved a therapeutic hypoprothrombinemia in 48 hours, 72 per cent in 72 hours.
By the arbitrary standards given, 47 per cent of all treated patients had an excellent therapeutic control, an additional 20 per cent had good control and only 4 per cent had poor to bad control. There were no fatalities in the series of 109 treated patients (or of the total of about 200 patients who received Dipaxin) and no serious complications. Bleeding phenomena were surprisingly few, and only one patient (of the total of 109) who had developed hematuria required special attention. It had been demonstrated that vitamin K compounds (especially K1) readily correct Dipaxin hypoprothrombinemia and again in this instance, 100 mg. of vitamin K, immediately halted the hematuria. Unlike other experience with another indandione compound, Hedulin, which has been reported to induce signs of renal toxicity,1' no specific evidence of parenchymal damage to the kidney has appeared. No other outstanding toxic manifestation was observed; even in patients receiving the drug daily and continuously for periods of 6 to 18 months.
In a conference on therapy, Wright3 has indicated that his objective of optimal therapeutic prothrombin activity for long-term anticoagulant therapy is to maintain the 25 to 50 per cent range. The standards used in this study with a relatively small group of patients receiving long-term Dipaxin therapy were somewhat more taxing since a lower range (10 to 30 per cent) was sought, and yet the control of prothrombin levels was accomplished with ease in almost all subjects even though the ambulant patient had estimations done only once every two or three weeks. In another report, Tullock and Wright '2 point out that in 227 patients who received coumarin anticoagulants for four weeks or more, there was one hemorrhagic death and 70 hemorrhagic episodes in 43 patients. In the 20 patients of this study who received Dipaxin for more than four weeks there were observed only two minor hemorrhagic experiences, an incidence far less than that experienced with the coumarin agents. Bay and his coworkers'3 have also recently reported on the use of Dicumarol in long-term therapy and they record an experience with a large number of minor, and occasionally massive, hemorrhagic tendencies. Despite use of weekly prothrombin determinations they felt that their control of therapy was relatively poor.
From the specific viewpoint of affording a safer and more predictable agent for long-term anticoagulant care, it would appear that Dipaxin merits further clinical trial. CONCLUSIONS 1. A new anticoagulant, Dipaxin (diphenylacetyl-1,3-indandione), has been studied in 200 human subjects. It has effectively induced a therapeutic hypoprothrombinemia in 48 to 72 hours and with repeated doses has sustained such hypoprothrombinemia in some patients for 18 months.
2. On a weight basis, it appears to be the most potent hypoprothrombinemic agent known. Its anticoagulant properties are readily overcome with vitamin K, the natural vitamin being more effective than the synthetic.
3. A group of 109 patients with thromboembolic indications received Dipaxin as specific therapy and 11 patients were maintained on ambulant anticoagulant care from 3 to 18 months. Control of anticoagulant therapy was impressive for its relative ease, reproducibility and predictability of response, absence of toxic phenomena and extremely low order of bleeding complications.
4. The agent appeared to be especially suitable for long-term maintenance control where prothrombin estimations could be made only at intervals of several weeks. 
